Dayvigo

Adult patients w/ insomnia characterized by sleep onset difficulties &/or sleep maintenance.

Adult 5 mg once daily immediately before bedtime, w/ at least 7 hr remaining before planned awakening time. Max: 10 mg once daily. Moderate hepatic impairment & co-administration w/ weak CYP3A inhibitor Max: 5 mg once daily.

Should be taken on an empty stomach: Take immediately before bedtime. Sleep induction may be delayed if taken at the same time or right after meals.

Hypersensitivity. Narcolepsy. Concomitant use w/ strong or moderate CYP3A inhibitors. Severe hepatic impairment.

Patients w/ organic brain disorders; moderate & severe resp function disorder; moderate or severe obstructive sleep apnea & COPD. Consider the necessity of continuing use when symptoms improve & ensure that Dayvigo is not aimlessly administered. Possible sleep paralysis, hypnagogic/hypnopompic hallucinations & cataplexy-like symptoms. Worsening of depression/suicidal ideation; carefully & immediately evaluate emergence of any new behavioural sign or symptom of concern. Immediately discontinue use if patient experiences complex sleep behaviours including sleep-walking, sleep-driving & engaging in other activities while not fully awake. Concomitant use w/ other drugs for insomnia. May induce drowsiness, attention impairment, concentration & reflex movements; avoid potentially hazardous activities (eg, operating machinery or driving a motor vehicle). Mild & moderate hepatic impairment. Severe renal impairment. Pregnant or possibly pregnant women. Lactation. Childn. Elderly.

Somnolence, headache; malaise.

Incidence of AR may be increased w/ moderate & strong CYP3A inhibitors (eg, itraconazole, clarithromycin, erythromycin, fluconazole, verapamil). Effects may be increased by weak CYP3A inhibitors (eg, ranitidine). Effects may be decreased by CYP3A inducers (eg, rifampicin, phenytoin). May enhance CNS depressant effects of phenothiazine & barbiturate derivatives. Additive decreases in psychomotor functions w/ alcohol.

Hypnotics & Sedatives

N05CJ02 - lemborexant ; Belongs to the class of orexin receptor antagonists. Used as hypnotics.

POM